We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis, the maker of a generic form of Zantac, said Wednesday it will stop selling the medicine after investigations suggested that generic and branded versions contain a known carcinogen.